A Phase 2 interventional study of Albumin infusion and Placebo Injection in Ischemic Stroke, sponsored by University Hospital Hradec Kralove. Recruiting at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by University Hospital Hradec Kralove · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Ischemic Stroke with a site in Czechia — 8 open to participants now, 10 under way, 1 of them phase 3. Ischemic Stroke · Czechia.
Among the 29 studies in Ischemic Stroke with a site in Czechia, this one is the 18th largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2026, is one of 7 in phase 2, and was the 29th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →8 of the 29 studies in Ischemic Stroke with a site in Czechia are open now. Recruiting first, the newest first:
University Hospital Ostrava · Sites in Czechia
Ages 18+
University Hospital Olomouc · Sites in Czechia
Ages 18+
University Hospital Ostrava · Sites in Czechia
Ages 18–85
University Hospital Ostrava · Sites in Czechia
Ages 18+
Elena Gurkova · Sites in Czechia
Ages 18–65
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 7 · Phase 4 2
First in 2003; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 532 across the 21 interventional studies, 520 across the 7 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 29 have an industry lead sponsor. The 10 most frequent:
University Hospital Hradec Kralove is the lead sponsor of 49 studies on the registry; 15 are open to participants now.
University Hospital Hradec Kralove has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
3 of the studies in Ischemic Stroke with a site in Czechia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06085612University Hospital OlomoucImpact of Significant Carotid Stenosis on Retinal Perfusion Measured Via Automated Retinal Oximetry | 2027-01-01 |
| NCT07415655University Hospital Hradec KraloveModulation of Cerebral Ischemia by Albumin | 2027-02-01 |
| NCT04075084Biotronik SE & Co. KGObservation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs) | 2027-05-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 29 studies in Ischemic Stroke with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A single-center, open-label, randomized, placebo-controlled, prospective phase II clinical trial to investigate the efficacy of low-dose albumin in patients with ischemic stroke with an indication for vasographic intervention. The clinical trial consists of the following phases: Screening, randomization, treatment phase - administration of albumin/placebo and vasographic intervention (with the duration of all these 3 phases in the order of hours) and a follow-up phase, which takes place first in the intensive care unit (ICU) and then in a standard ward and lasts 90 (±7) days. The clinical trial ends with the End of Study/Day 90 visit. The total maximum duration of patient participation in the clinical trial is therefore 97 days, including Follow-up.
Ischemic stroke is caused by local perfusion impairment due to thromboembolism or thrombosis at the site of perfusion impairment. The damaged brain area is projected into the patient's neurological clinical picture. The primary stroke cannot be influenced by therapeutic procedures, however, the area of the so-called penumbra (the surroundings of the ischemic lesion, where vasoreactivity is impaired and the blood-brain barrier is more or less damaged) can be, which is the main goal of therapy, as well as improving the neurological clinical outcome of patients as much as possible (thrombolysis, neuroangiointervention). Research over the past 20 years has highlighted the importance of the endothelial glycocalyx (EG) and has proposed a number of concepts and substances with a protective and reparative effect.
Albumin has come to the forefront of interest. The study assumes a benefit for patients in the form of non-circulatory effects of administered albumin: improvement of EG condition in the penumbra area of the ischemic focus, improvement of microrheology, and antioxidant protection. Albumin therapy has been used for 80 years and is generally well tolerated. Allergy to albumin is rare, as it is a protein of the body's own from healthy donors. The concomitantly used medicinal products are highly purified. The selected dosage should not endanger the patient in any way in terms of circulatory overload, pulmonary edema, and, we assume, also in terms of bleeding into the ischemic focus of the brain.
Study drug: albumin. Any albumin available on the market in the dose and strength specified in the protocol can be used. The reference SmPC is Alburex (manufacturer CSL Behring). Placebo: Fresenius Kabi 0.9% saline solution.
It is planned to enroll 100 patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Albumin infusion
Drug: Placebo Injection
Albumin will be given to the eligible patients during the vasographic intervention intravenously within 20 minutes. The dose is unified for all participants - 100 ml of 20 % human serum albumin.
Also known as: Albumin
Normal saline as a placebo will be given to the eligible patients during the vasographic intervention intravenously within 20 minutes. The dose is unified for all participants: 100 ml of 0,9 % sodium chloride.
Also known as: Normal saline
Syndecan-1 serum concentration
Assessment of syndecan-1 in the serum by the ELISA method. Results are a concentration in ng/ml.
Time frame: Baseline, in 12 hours, 24 hours, 48 hours and 72 hours.
Glycoyaminoglycans in the urine concentration
The concentration of all the glycosaminoglycans excreted into the urine. The assessment by spectrophotometry. Concentration in mg/ml.
Time frame: Baseline, in 12 hours, 24 hours, 48 hours and 72 hours.
The brain ischemia volume
Assessment of the ischemia of the brain after a vasographic intervention on the follow-up CT scan calculated using a three-dimensional equation.
Time frame: In 12 to 24 hours.
Neurological outcome
Neurological outcome assessed by the modified Rankin scale (7-level scale.
Time frame: 90 days.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 11 months after the start.
Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 11 months is below that.
Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albumins
University Hospital Hradec Kralove